Journal of Microbiology

Research Article

Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease: Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae Suk; J. Microbiol. 2025;63(2):e2411002. Published online February 27, 2025; DOI: https://doi.org/10.71150/jm.2411002

226 View
15 Download

Abstract PDF: Synbiotics have become a new-age treatment tool for limiting the progression of metabolic dysfunction-associated steatotic liver disease; however, inclusive comparisons of various synbiotic treatments are still lacking. Here, we have explored and evaluated multiple synbiotic combinations incorporating three distinctive prebiotics, lactitol, lactulose and fructooligosaccharides. Of the synbiotic treatments evaluated, a combination of fructooligosaccharides and probiotics (FOS+Pro) exhibited superior protection against western diet-induced liver degeneration. This synbiotic (FOS+Pro) combination resulted in the lowest body weight gains, liver weights and liver/body weight ratios. The FOS+Pro synbiotic combination substantially alleviated liver histopathological markers and reduced serum AST and cholesterol levels. FOS+Pro ameliorated hepatic inflammation by lowering expression of proinflammatory markers including TNF-α, IL-1β, IL-6, and CCL2. FOS+Pro significantly improved steatosis by restricting the expression of lipid metabolic regulators (ACC1, FAS) and lipid transporters (CD36) in the liver. These findings are critical in suggesting that synbiotic treatments are capable of restraining western diet-induced metabolic dysfunction in the liver. Additionally, this study demonstrated that adding probiotic strains amplified the effectiveness of fructooligosaccharides but not all prebiotics.

Journal Article

Gut Lactobacillus and Probiotics Lactobacillus lactis/rhamnosis Ameliorate Liver Fibrosis in Prevention and Treatment: Sung Min Won , Na Young Lee , Ki&# , Haripriya Gupta , Satya Priya Sharma , Kyung Hwan Kim , Byoung Kook Kim , Hyun Chae Joung , Jin Ju Jeong , Raja Ganesan , Sang Hak Han , Sang Jun Yoon , Dong Joon Kim , Ki Tae Suk; J. Microbiol. 2023;61(2):245-257. Published online February 6, 2023; DOI: https://doi.org/10.1007/s12275-023-00014-y

47 View
0 Download
9 Web of Science
8 Crossref

The progression and exacerbation of liver fibrosis are closely related to the gut microbiome. It is hypothesized that some probiotics may slow the progression of liver fibrosis. In human stool analysis [healthy group (n = 44) and cirrhosis group (n = 18)], difference in Lactobacillus genus between healthy group and cirrhosis group was observed. Based on human data, preventive and therapeutic effect of probiotics Lactobacillus lactis and L. rhamnosus was evaluated by using four mice fibrosis models. L. lactis and L. rhamnosus were supplied to 3,5-diethoxycarbonyl-1,4-dihydrocollidine or carbon tetrachloride-induced liver fibrosis C57BL/6 mouse model. Serum biochemical measurements, tissue staining, and mRNA expression in the liver were evaluated. The microbiome was analyzed in mouse cecal contents. In the mouse model, the effects of Lactobacillus in preventing and treating liver fibrosis were different for each microbe species. In case of L. lactis, all models showed preventive and therapeutic effects against liver fibrosis. In microbiome analysis in mouse models administered Lactobacillus, migration and changes in the ratio and composition of the gut microbial community were confirmed. L. lactis and L. rhamnosus showed preventive and therapeutic effects on the progression of liver fibrosis, suggesting that Lactobacillus intake may be a useful strategy for prevention and treatment.

Citations

Citations to this article as recorded by

Enhancing the application of probiotics in probiotic food products from the perspective of improving stress resistance by regulating cell physiological function: A review
Dingkang Wang, Ruijie Xu, Sha Liu, Xiaomin Sun, Tianxiao Zhang, Lin Shi, Youfa Wang
Food Research International.2025; 199: 115369. CrossRef
Lactobacillus gasseri BNR17 and Limosilactobacillus fermentum ABF21069 Ameliorate High Sucrose-Induced Obesity and Fatty Liver via Exopolysaccharide Production and β-oxidation
Yu Mi Jo, Yoon Ji Son, Seul-Ah Kim, Gyu Min Lee, Chang Won Ahn, Han-Oh Park, Ji-Hyun Yun
Journal of Microbiology.2024; 62(10): 907. CrossRef
Probiotics modulation of the endotoxemic effect on the gut and liver of the lipopolysaccharide challenged mice
Gyan Babu, Banalata Mohanty
Drug and Chemical Toxicology.2024; : 1. CrossRef
Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
Xiaofei Zhu, Ziyuan Zhou, Xiaxia Pan
Frontiers in Microbiology.2024;[Epub] CrossRef
Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis
Xue Li, Xinyi Xu, Sian Tao, Yue Su, Li Wen, Dong Wang, Jibin Liu, Quansheng Feng
Frontiers in Pharmacology.2024;[Epub] CrossRef
Assessment of probiotic properties of lactic acid bacteria isolated from an artisanal Colombian cheese
Samantha Roldán-Pérez, Sara Lucía Gómez Rodríguez, José Uriel Sepúlveda-Valencia, Orlando Simón Ruiz Villadiego, María Elena Márquez Fernández, Olga I. Montoya Campuzano, Mónica María Durango-Zuleta
Heliyon.2023; 9(11): e21558. CrossRef
Agrocybe aegerita Polysaccharide Combined with Bifidobacterium lactis Bb-12 Attenuates Aging-Related Oxidative Stress and Restores Gut Microbiota
Xiaoyan Liu, Yanyu Feng, Hongmin Zhen, Lina Zhao, Hongqiang Wu, Bin Liu, Guangsen Fan, Aijun Tong
Foods.2023; 12(24): 4381. CrossRef
Probiotics and liver fibrosis: An evidence-based review of the latest research
Lin Cheng, Jianyou Shi, Haoyuan Peng, Rongsheng Tong, Yonghe Hu, Dongke Yu
Journal of Functional Foods.2023; 109: 105773. CrossRef

First
Prev
Page of 1
Next
Last

Search